Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15110351 | 0.85 | ACACB (0.46) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL10768177 | 0.83 | PKM (0.78) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL29468019 | 0.82 | MAP4K4 (0.63) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL2429842 | 0.81 | PKM (0.58) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL5567984 | 0.81 | GAA (0.63) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL10066174 | 0.81 | LMNA (0.63) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL5779694 | 0.80 | PKM (0.39) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL5779696 | 0.80 | PKM (0.39) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL27783823 | 0.78 | GAA (0.59) | LMNAPKMNOTUMGAAPTK2 | |
| SCHEMBL1160951 | 0.78 | PKM (0.64) | LMNAPKMNOTUMGAAPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025067540-A1 | PYRAZOLOTRIAZINE AND PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-03 | — | — | WO | disclosed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| CN-117736134-A | Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases | 耶鲁大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-2714667-B1 | AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | DESAI LAXMAN S (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-2714667-B1 | AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | DESAI LAXMAN S (US) | 2020-11-25 | — | — | EP | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1720882-A2 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7119200-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-06-15 | — | — | US | disclosed |
| CN-1735614-A | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORP (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2005077954-A2 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1537116-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004022561-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | LMNA 1706/4885PKM 438/4885NOTUM 4098/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | LMNA 3171/4885PKM 2962/4885NOTUM 2360/4885 |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | AR, VHL, MDM2 | LMNA 2853/4885PKM 2959/4885NOTUM 2102/4885 |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ESRRA, MDM2 | LMNA 3173/4885PKM 2985/4885NOTUM 2145/4885 |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDK5 | LMNA 2221/4885PKM 552/4885NOTUM 4192/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | LMNA 2762/4885PKM 3006/4885NOTUM 2823/4885 |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | LMNA 3171/4885PKM 2962/4885NOTUM 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.